ID: ALA3125284

Max Phase: Preclinical

Molecular Formula: C25H32N6O4

Molecular Weight: 480.57

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCc1cc(C(=O)N[C@@H]2C[C@@H](C(=O)NCCN(C)C)N(C(=O)c3coc4ccccc34)C2)n(C)n1

Standard InChI:  InChI=1S/C25H32N6O4/c1-5-16-12-20(30(4)28-16)24(33)27-17-13-21(23(32)26-10-11-29(2)3)31(14-17)25(34)19-15-35-22-9-7-6-8-18(19)22/h6-9,12,15,17,21H,5,10-11,13-14H2,1-4H3,(H,26,32)(H,27,33)/t17-,21+/m1/s1

Standard InChI Key:  IQMZLMRYRSOCEC-UTKZUKDTSA-N

Associated Targets(non-human)

Mycobacterium tuberculosis 203094 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Enoyl-[acyl-carrier-protein] reductase 1329 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 480.57Molecular Weight (Monoisotopic): 480.2485AlogP: 1.42#Rotatable Bonds: 8
Polar Surface Area: 112.71Molecular Species: BASEHBA: 7HBD: 2
#RO5 Violations: 0HBA (Lipinski): 10HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 8.51CX LogP: 0.56CX LogD: -0.58
Aromatic Rings: 3Heavy Atoms: 35QED Weighted: 0.50Np Likeness Score: -1.39

References

1. Encinas L, O'Keefe H, Neu M, Remuiñán MJ, Patel AM, Guardia A, Davie CP, Pérez-Macías N, Yang H, Convery MA, Messer JA, Pérez-Herrán E, Centrella PA, Alvarez-Gómez D, Clark MA, Huss S, O'Donovan GK, Ortega-Muro F, McDowell W, Castañeda P, Arico-Muendel CC, Pajk S, Rullás J, Angulo-Barturen I, Alvarez-Ruíz E, Mendoza-Losana A, Ballell Pages L, Castro-Pichel J, Evindar G..  (2014)  Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA.,  57  (4): [PMID:24450589] [10.1021/jm401326j]

Source